Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Journey Medical CorporationNASDAQ: DERM
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $989K fell 25.2% year over year, behind the -1.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 44.3% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Stock-based compensation amounted to 10.2% of revenue in FY2025, down 0.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -1.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.29M USD
- Year-over-year change
- +3.1%
- 4-year CAGR
- +26.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.29M | +3.1% |
| FY2024 | 2024-12-31 | 6.1M | +134.0% |
| FY2023 | 2023-12-31 | 2.61M | -41.1% |
| FY2022 | 2022-12-31 | 4.43M | +79.4% |
| FY2021 | 2021-12-31 | 2.47M | — |
Stock-Based Compensation vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.0% is the 6th highest of 10, against a peer median of +7.9%.
- Stock-based compensation amounts to 9.2% of revenue for DERM, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $11.86M USD | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $11.45M USD | -1.6% | -90.4% | 10.1% | |
| LTM Mar 2026 | $10.44M USD | +36.3% | -2.0% | 587.9% | |
| LTM Mar 2026 | $8.72M USD | +217.8% | — | 90.9% | |
| LTM Mar 2026 | $6.24M USD | +33.6% | +18.6% | 12.2% | |
| LTM Mar 2026 | $5.95M USD | -1.0% | +12.4% | 9.2% | |
| LTM Mar 2026 | CA$3.45M CAD | -36.6% | — | 1.3% | |
| LTM Mar 2026 | $2.91M USD | -16.2% | +16.9% | 20.1% | |
| LTM Mar 2026 | €887K EUR | -82.2% | — | 5.4% | |
| Peer median (excluding DERM) | — | +7.9% | +17.7% | 20.1% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.